Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) (CONCOR-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04348656
Recruitment Status : Active, not recruiting
First Posted : April 16, 2020
Last Update Posted : March 4, 2021
Sponsor:
Collaborators:
Canadian Blood Services
Héma-Québec
University of Toronto
Université de Montréal
Weill Medical College of Cornell University
New York Blood Centre
Information provided by (Responsible Party):
McMaster University ( Hamilton Health Sciences Corporation )

Tracking Information
First Submitted Date  ICMJE April 13, 2020
First Posted Date  ICMJE April 16, 2020
Last Update Posted Date March 4, 2021
Actual Study Start Date  ICMJE May 14, 2020
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 2, 2021)
Intubation or death [ Time Frame: Day 30 ]
Endpoint of the need for intubation or patient death
Original Primary Outcome Measures  ICMJE
 (submitted: April 13, 2020)
Intubation or death in hospital [ Time Frame: Day 30 ]
Endpoint of the need for intubation or patient death in hospital
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 27, 2020)
  • Need for Intubation [ Time Frame: Day 30 ]
    Endpoint of the need for intubation before 30 days
  • Time to intubation [ Time Frame: Day 30 ]
    Time in hours to intubation from randomization
  • Ventilator-free days [ Time Frame: Day 30 ]
    Endpoint of the number of days off ventilator at 30 days
  • In-hospital death [ Time Frame: 90 days ]
    In-hospital death censored at 90 days
  • Time to in-hospital death [ Time Frame: Day 90 ]
    Time to in-hospital death at 90 days
  • Death at 30 days [ Time Frame: 30 days ]
    Death at 30 days
  • Length of stay in intensive care unit (ICU) [ Time Frame: Day 30 ]
    Date of intensive care unit admission (first date and total number of days)
  • Length of stay in hospital [ Time Frame: Day 30 ]
    Date of hospital admission (first date and total number of days)
  • Need for extracorpeal membrane oxygenation (ECMO) [ Time Frame: Day 30 ]
    First date on ECMO and total number of days
  • Need for renal replacement therapy [ Time Frame: Day 30 ]
    Need for renal replacement therapy
  • Development of myocarditis [ Time Frame: Day 30 ]
    New myocarditis
  • Adverse events and serious adverse events [ Time Frame: Day 30 ]
    Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)
  • CCP transfusion-associated adverse events (AE) [ Time Frame: 30 days ]
    CCP transfusion-associated adverse events (AE)
Original Secondary Outcome Measures  ICMJE
 (submitted: April 13, 2020)
  • Intubation [ Time Frame: Day 30 ]
    Endpoint of the need for intubation before 30 days
  • Time to intubation [ Time Frame: Day 30 ]
    Time in hours to intubation from randomization
  • Ventilator-free days [ Time Frame: Day 30 ]
    Endpoint of the number of days off ventilator at 30 days
  • In-hospital death [ Time Frame: 90 days ]
    In-hospital death censored at 90 days
  • Time to in-hospital death [ Time Frame: Day 90 ]
    Time to in-hospital death at 90 days
  • Death at 30 days [ Time Frame: 30 days ]
    Death at 30 days
  • Length of stay in intensive care unit (ICU) [ Time Frame: Day 30 ]
    Date of intensive care unit admission (first date and total number of days)
  • Length of stay in hospital [ Time Frame: Day 30 ]
    Date of hospital admission (first date and total number of days)
  • Need for extracorpeal membrane oxygenation (ECMO) [ Time Frame: Day 30 ]
    First date on ECMO and total number of days
  • Need for renal replacement therapy [ Time Frame: Day 30 ]
    Need for renal replacement therapy
  • Myocarditis [ Time Frame: Day 30 ]
    New myocarditis
  • Adverse events and serious adverse events [ Time Frame: Day 30 ]
    Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)
  • Transfusion-associated adverse events (AE) [ Time Frame: 30 days ]
    Transfusion-associated adverse events (AE)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
Official Title  ICMJE A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Brief Summary

There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection.

The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19.

It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay.

This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.

Detailed Description

Problem to be addressed: In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients.This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19.Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise [1] in many countries over the coming weeks to months.Global efforts to evaluate novel antivirals and therapeutic strategies to treat COVID-19 have intensified. There is an urgent public health need for rapid development of novel interventions. At present, there is no specific antiviral therapy for coronavirus infections.

Passive immunization:Passive immunization consists in the transfer of antibodies from immunized donor to non-immunized individual in order to transfer transient protection against an infective agent. A physiological example of passive immunization is the transfer of maternal IgG antibodies to the foetus through the placenta to confer humoral protection to newborns in the first years of life. Passive immunization differs from active immunization in which the patient develops their own immune response following contact with the infective agent or vaccine.

Known potential risks and benefits: There is a theoretical risk of antibody-dependent enhancement of infection (ADE) through which virus targeted by non-neutralizing antibodies gain entry into macrophages. Another theoretical risk is that antibody administration to those exposed to SARS-CoV-2 may avoid disease but modify the immune response such that those individuals mount attenuated immune responses, which would leave them vulnerable to subsequent re-infection. Finally, there are risks associated with any transfusion of plasma including transmission of blood transmitted viruses (e.g. HIV, HBV, HCV, etc.), allergic transfusion reactions, including anaphylaxis, febrile non hemolytic transfusion reaction, transfusion related acute lung injury (TRALI), transfusion associated cardiac overload (TACO), and hemolysis should ABO incompatible plasma be administered. Potential benefits of COVID-19 convalescent plasma include improved survival, improvement in symptoms, decreased risk in intubation for mechanical ventilation, decrease risk of intensive care unit (ICU) admission, shortened hospitalization time and suppression of viral load.

Mechanism of action: Transfusion of apheresis frozen plasma (AFP) from COVID-19 convalescent patients allows the transfer of donor neutralizing antibodies directed against SARS-CoV2 antigens to the recipient, thus allowing the generation of passive immunization. Naturally produced human antibody are polyclonal, meaning they are directed against a variety of different viral antigens and epitopes allowing for a general neutralizing effect against the virus rather than focussing on a specific target. Administration of convalescent plasma has been associated with rapid decrease in viral load. It is also possible that passive immunization contributes to improved cell-mediated immunity by favoring the phagocytosis and presentation of viral antigens to host T cells.

Participant recruitment:Only hospitalized COVID-19 patients are eligible so recruitment efforts will be focused on identified consecutive patients admitted to hospital with acute COVID-19 infection. No other external recruitment efforts are planned. At each participating hospital, a process for identifying patients with COVID-19 will be established.

Donor recruitment for Canadian sites: Recovered COVID-19 patients will be identified as potential donors in collaboration with provincial public health services, local health authorities, and individual co-investigators involved in the study. Potential donors may also be recruiting following self-identification on the routine donor questionnaire or through social media. They will be contacted by phone and invited to participate in the program as potential donors. After obtaining verbal consent and reviewing donor selection criteria, eligible participants will be directed to a Héma-Québec collection or Canadian Blood Services apheresis collection site in their area to donate.

Criteria for donors: All donors will need to meet the criteria set forth in the Manual of donor selection criteria in use at Héma-Québec or Canadian Blood ServicesIn addition, donors will require:

  • Prior diagnosis of COVID-19 documented by a PCR test at time of infection or by positive anti-SARS-CoV-2 serology following infection
  • Male donors, or female donors with no pregnancy history or with negative anti-HLA antibodies
  • At least 6 days since last plasma donation
  • Provided informed consent
  • A complete resolution of symptoms at least 14 days prior to donation

Donor recruitment for United States sites: Recovered COVID-19 patients are being recruited through the New York Blood Center and Weill Cornell Medicine in separate protocols. Potential donors can self-refer via websites but also be referred by physicians or identified via the medical record system. Only donors with laboratory-confirmed history of COVID-19 will be screened. After providing consent and reviewing FDA and NYBC donor eligibility criteria, donors are screened for the presences of SARS-CoV-2 virus in the nasopharynx if screening within 14 days of complete resolution in accordance with current FDA guidance. Criteria for donation are subject to change based on future revision of FDA guidance. Those found to be eligible will be referred to NYBC for donation.

Criteria for donors:

  • Provision of informed consent
  • Aged 18 to 70 years. Donors are not longer eligible after their 71st birthday.
  • Documented molecular diagnosis of SARS-CoV-2 by RT-PCR by nasopharyngeal swab, oropharyngeal swab, or sputum or detection of anti-SARS-CoV-2 IgG in serum.
  • Complete resolution of COVID-19 symptoms at least 14 days prior to donation
  • Not currently pregnant or pregnant within 6 weeks by self-report
  • Male donors, or females with no pregnancy history or with negative anti-HLA antibodies
  • Meets blood donor criteria specified by NYBC, which is consistent with FDA regulations.

Donors will be allowed to donate every 7 days. The following information will be collection from donors: ABO group, sex, age, date of onset of symptoms (when available), date of resolution of symptoms (when available), CCP collection date(s).

Randomization procedures: Patients will be randomized in a 2:1 ratio (convalescent plasma vs standard of care). Patients will be randomized using a secure, concealed, computer-generated, web-accessed randomization sequence. Randomization will be stratified by centre and age (<60 and ≥ 60 years). Within each stratum, variable permuted block sized will be used. This approach will ensure that concealment of the treatment sequence is maintained.

Duration of follow-up: Subjects will be followed daily until hospital discharge or death. Patients discharged from hospital before Day 30 will be contacted by telephone on Day 30 ± 3 days to ascertain any AEs, vital status (dead/alive), hospital readmission and need for mechanical ventilation after discharge. Patients discharged from hospital will be contacted at Day 90+/- 7 days to determine vital status. Patients with a prolonged hospital admission will be censored at Day 90. The local study coordinator will collect all study data and record the data in the electronic CRF or paper CRF as per study procedures for each site.

Duration of study: For an individual subject, the study ends 90 days after randomization. The overall study will end when the last randomized subject has completed 90 day follow-up. We estimate that all patient will be enrolled in a period of 6 months, data on the primary endpoint will be available 30 days after last patient enrollment and data on all secondary endpoints will be available after 90-day from last patient enrollment.

Sample size considerations: Assuming a baseline risk of intubation or death of 30% in hospitalized patients with standard of care, a sample size of 1200 (800 in the convalescent plasma arm, and 400 in the standard of care arm) would provide 80% power to detect a relative risk reduction of 25% with convalescent plasma therapy using a 2-tailed test at level α = 0.05 and a 2:1 randomization.

Interim analysis: A single interim analysis is planned when the primary outcome (intubation or mortality at 30 days) is available for 50% of the target sample. An O'Brien-Fleming stopping rule will be used at that time, but treated as a guideline, so there is minimal impact on the threshold for statistical significance for the final significance test of the primary outcome. A DSMB will monitor ongoing results to ensure patient well-being and safety as well as study integrity. The DSMB will be asked to recommend early termination or modification only when there is clear and substantial evidence of a treatment difference.

Final analysis plan: The primary analysis will be based on the intention-to-treat population which will include data from all individuals who have been randomized. Outcomes will be attributed to the arm to which individuals were randomized irrespective of whether they received the planned intervention (e.g. plasma from a convalescent COVID-19 donor).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE COVID-19
Intervention  ICMJE Biological: Convalescent plasma
Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
Study Arms  ICMJE
  • Experimental: Convalescent plasma
    ~500 mL ABO compatible convalescent apheresis plasma
    Intervention: Biological: Convalescent plasma
  • No Intervention: Standard of care
    Treated as per institutional standard of care.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: April 13, 2020)
1200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2021
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • ≥16 years old (>18 years of age in the United States)
  • Admitted to hospital with confirmed COVID-19 respiratory illness
  • Receiving supplemental oxygen
  • 500 mL of ABO compatible convalescent plasma is available

Exclusion Criteria:

  • Onset of symptoms >12 days prior to randomization
  • Intubated or plan in place for intubation
  • Plasma is contraindicated (e.g. history of anaphylaxis from transfusion)
  • Decision in place for no active treatment
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Brazil,   Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04348656
Other Study ID Numbers  ICMJE CONCOR-1
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party McMaster University ( Hamilton Health Sciences Corporation )
Study Sponsor  ICMJE Hamilton Health Sciences Corporation
Collaborators  ICMJE
  • Canadian Blood Services
  • Héma-Québec
  • University of Toronto
  • Université de Montréal
  • Weill Medical College of Cornell University
  • New York Blood Centre
Investigators  ICMJE
Principal Investigator: Donald M Arnold, MD McMaster University
PRS Account McMaster University
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP